Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




CSF Biomarker Meprin-Beta Increases in Alzheimer’s Disease

By LabMedica International staff writers
Posted on 20 Oct 2026

Alzheimer’s disease involves biological changes in the brain, including the accumulation of beta-amyloid. More...

Cerebrospinal fluid provides access to molecules linked to nervous system processes, making it a valuable medium for investigating these changes. Extending this molecular understanding, new findings show elevated levels of meprin-β in both brain tissue and cerebrospinal fluid from people with Alzheimer’s disease.

The Institute for Neurosciences (Alicante, Spain), a joint center of the Miguel Hernández University of Elche and the Spanish National Research Council, led the study of meprin-β in Alzheimer’s disease. Meprin-β is an enzyme that can exist in immature inactive and mature active forms. The researchers analyzed these forms separately to determine how they change during disease progression.

Alzheimer’s disease involves processing of amyloid precursor protein by enzymes that include BACE1 and other beta-secretases, including meprin-β. The team studied frontal cortex samples from patients at different stages of Alzheimer’s disease and compared them with samples from people without Alzheimer’s disease. Samples were classified by Braak stage, a scale used to describe progression of pathology in the brain.

The active form of meprin-β increased in more advanced Braak stages, while this increase was not observed in early stages. The researchers also detected increased MEP1B messenger RNA at intermediate and advanced stages. In cerebrospinal fluid samples, they found increased levels of the active form of meprin-β in people with Alzheimer’s disease.

To examine a possible relationship with beta-amyloid accumulation, the team analyzed cerebrospinal fluid from transgenic rats that develop pathology associated with beta-amyloid accumulation. The active form of meprin-β was also increased in these animals. Human neurons derived from induced pluripotent stem cells showed a significant increase in meprin-β after exposure to the beta-amyloid peptide Aβ42.

The findings were published in Alzheimer’s Research & Therapy in 2026. The study involved the University Medical Center Mainz, the University of Barcelona and the University of Gothenburg. The authors suggest that meprin-β could be involved in processes related to amyloid precursor protein processing, while noting that further studies are needed to determine its potential use as an indicator of disease.

“Until now, much of the attention has focused on BACE1 as a relevant β-secretase in Alzheimer’s disease. Our work shows that there is another protein, meprin-β, whose active form is increased in the brain and cerebrospinal fluid of people with this disease,” said Javier Sáez Valero, a researcher at the Institute for Neurosciences and the study’s principal investigator.

“When we expose human neurons to beta-amyloid, we also observe an increase in meprin-β. This provides an experimental link between one of the hallmarks of Alzheimer’s disease and the alteration we have found in patient samples,” said Sergio Escamilla, first author of the study.

Related Links
Institute for Neurosciences


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Led by Professor Sherry Chan Kit-wa (middle), the HKUMed research team provides the first large-scale Chinese population evidence to support reviewing Hong Kong’s long-term blood-monitoring requirements for clozapine use. (Photo courtesy of HKUMed)

Study Supports Review of Long-Term Blood-Monitoring Guidelines for Clozapine

Treatment-resistant schizophrenia (TRS) is a severe form of schizophrenia for which clozapine remains the only antipsychotic specifically approved by the U.S. Food and Drug Administration (FDA).... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image

Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil

Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.